Related to Merck KGaA Nabs Threshold’s Late-Stage Hypoxia-Targeting Anticancer Drug for Initial $25M

• KalVista Pharmaceuticals Launches with £8M in Series A Funding
  
• NovAliX Inks SPR-Based Fragment Screening Deal for Lead Discovery with Galapagos
  
• Debiopharm Negotiates License to Ascenta’s Clinical-Stage Anticancer IAP Inhibitor
  
• Oncothyreon to Develop Sanford-Burnham Small Molecule Targeting Cancer
  
• Aduro BioTech Wins $250K in SBIR Grants and Contract with UNM for Vaccine Development
  
• Aestus Gains Rights to Prosidion’s Neuropathic Pain Drug and Expands Collaboration with ALS TDI
  
• BI and Nuevolution Leverage Chemetics Platform in Drug Discovery Collaboration
  
• Tokai Raises $23M to Support Phase II Development of Prostate Cancer Drug
  
• ViroPharma Gives Intellect Neurosciences $6.5M for Exclusive Worldwide Rights to OX1
  
• G-Zero Awarded $3.6M to Advance Pharmacoquiescence Approach to Radiomitigation
  
• Servier and Galapagos Embark on Cancer Drug Alliance Valued at €260M
  
• Karyopharm Teams with Rega Institute to Bolster Nuclear Export Inhibitor Pipeline
  
• Life Technologies to Develop Companion Diagnostic for GSK’s Cancer Immunotherapy
  
• Biogen Idec and Portola Forge $45M Pact to Tackle Autoimmune and Inflammatory Diseases
  
• Karyopharm Raises $10M to Expand Planned Phase I Trials with Anticancer SINE Candidates
  
• BMS and Aslan Establish Deal for Early Clinical-Stage Anticancer cMET Inhibitor
  
• Daiichi Sankyo Licenses Phase I-Ready Cancer Drug Developed Through ArQule Partnership
  
• Scientists Identify Gene Variant that Doubles Background Risk of Melanoma
  
• NCI/NHGRI Taps Horizon's Gene-Editing Platform
  
• Insights on Melanoma's Resistance to Vemurafenib Revealed